Latest News

Catch up on this week's highlights in retina.

Eydenzelt is Celltrion's first FDA-approved biologic product in ophthalmology.

Biomarkers and fine-tuned staging are key to progress in improving retinal care, according to Fanka Gilevska, MD, PhD.

Ultra-high-resolution OCT advances retinal imaging, enabling detailed visualization of disease progression and potential therapeutic effects in eye conditions.

The Phase 1/2 ArMaDa trial is evaluating OCU410 (Ocugen), a gene therapy candidate for patients with dry age-related macular degeneration.

Sura-vec is intended to be a potential 1-time treatment consisting of the NAV AAV8 vector, which encodes an antibody fragment designed to inhibit vascular endothelial growth factor (VEGF).

Merck and EyeBio launch a pivotal trial for MK-3000, targeting diabetic macular edema with new treatment options to enhance patient outcomes.

The company can now initiate the Opti-GAIN (Optimized Geographic Atrophy INterventional) phase 1/2 clinical trial.

Additionally, the company also received Clinical Trial Authorization (CTA) approval from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA).

NPI-001 is Nacuity’s investigational therapy for the treatment of patients with retinitis pigmentosa (RP).

Patient response focused on perceived vision-related quality of life outcomes, investigators said.

Catch up on this week's highlights in retina.

The Eye Care Network spoke with Sebastian Wolf, MD, PhD, and Sophie Bonnin, MD, PhD, who presented new findings from the OCS-05 phase 2 ACUITY trial.

Behind the scenes of building impactful educational platforms in retina care

The trial results show promising for the evaluated gene therapy for the treatments of LCA, showing significant vision improvements in pediatric patients.

The characteristics of these inherited retinal diseases make it difficult to define objective, clinically meaningful outcomes that are sensitive enough to measure change over the course of a trial.

Broadwood Partners, who is against the merger, holds approximately 27.5% of the outstanding common stock of STAAR, making them the largest outside stockholder of STAAR.

Christine Kay, MD, presents new findings on MCO-010, a novel optogenetic therapy improving vision in retinitis pigmentosa patients at the Retina Society meeting.

Hear highlights from the Vit-Buckle Society and its presence at EURETINA 2025.

Catch up on this week's highlights in retina.

ISTH0036 demonstrates potential to prevent fibrosis, reduce retinal fluid, and improve vision in AMD and diabetic macular edema patients.

The newly approved technology delivers low-dose microcurrents through closed eyelids to stimulate retinal cells.

EURETINA's 25th anniversary meeting attracts 11,000 participants, showcasing cutting-edge research and fostering global networking among retina specialists.

The submission was based on the safety and efficacy data from the phase 3 (RHODOS) and phase 4 (LEROS) studies.

The window shop provision in the Alcon merger agreement enabled STAAR to accept a competing acquisition proposal and terminate the Alcon merger.

Luxa Biotechnology reveals promising phase 1/2a trial results for RPESC-RPE therapy, showing safety and potential vision restoration in patients with dry AMD.